Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment.

Liver-humanized chimeric mice (PXB-mice) are widely utilized for predicting human pharmacokinetics (PK) and as human disease models. However, residual metabolic activity of mouse hepatocytes in chimeric mice can interfere with accurate human PK estimation. Lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) treatment makes it possible to eliminate the shortcomings of chimeras and create new models. Therefore, we aimed to create a new model in which siRNA for mouse cytochrome P450 oxidoreductase () gene was encapsulated in LNP and administered to PXB-mice. We validated the siRNA-LNP system in PXB-mice, showing that a single intravenous injection of LNP-formulated mouse-specific siRNA against transthyretin () knocked down expression in the liver and decreased plasma mouse TTR levels without affecting hepatic expression and plasma human TTR levels. We produced mouse -specific siRNA with high silencing activity (siPOR(Mm)) and confirmed the efficient knockdown of expression in the livers of PXB-mice administered intravenously with LNP-encapsulated siPOR (siPOR(Mm)/LNP). siPOR(Mm)/LNP treatment suppressed 4'-hydroxywarfarin, making the -warfarin PK profile in PXB-mice more similar to that in humans. Thus, mouse-specific siRNA-LNP is a simple system to control gene expression in the remaining mouse hepatocytes of PXB-mice and create more humanized and invaluable models based on PXB-mice.